Senseonics (NYSE:SENS) shares rose today on first-quarter results that beat the consensus forecast. The Germantown, Md.–based diabetes management technology developer posted losses of –$249.5 million, or –68¢ per share, on sales of $2.8 million for the three months ended March 31, 2021, registering a massive bottom-line slide from losses of –$42.6 million this time one […]
Drug-Device Combinations
Insulet sues Roche over diabetes tech patent
Insulet (NSDQ:PODD) is suing Roche Diabetes Care in the U.K., claiming that Roche prematurely began selling tubeless insulin pumps covered by an Insulet patent three years before that patent expires. The trial for the lawsuit, filed in August 2020, began this week in the U.K. High Court. Get the full story on our sister site, Drug Delivery Business […]
Lyra Therapeutics rises on Q1 earnings
Lyra Therapeutics (NSDQ:LYRA) shares finished up on the day despite first-quarter results that missed the consensus earnings forecast. The Watertown, Mass.-based chronic rhinosinusitis (CRS) treatment developer posted losses of -$7.8 million, or -60¢ per share for the three months ended March 31, 2021, for a -84.4% bottom-line slide. Lyra’s EPS of -60¢ came in 48¢ behind […]
Camurus touts study of depot injection for opioid dependence
Camurus announced positive study results for its subcutaneous buprenorphine depot injections (Buvidal) for treating opioid dependence. Lund, Sweden-based Camurus’ 24-week, randomized, controlled trial compared patient-reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly Buvidal depot injections against daily sublingual buprenorphine. Results were published in JAMA Network Open yesterday. Get the full story at our sister site, […]
Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system
Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Get the full story at our sister site, […]
Insulet shares down after Q1 miss
Insulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations. The company, however, yesterday evening raised the low end of its revenue guidance range to 16–20%. The range was previously 15–20%. The Acton, Mass.-based company a net loss of […]
Ocular Therapeutix misses The Street on bottom-line leap
Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared […]
BD to spin off its diabetes business, Q2 earnings beat The Street
BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022. The Diabetes Care business saw $1.1 billion in sales during BD’s fiscal year ended Sept. 30, 2020, nearly half outside the U.S. The business manufactures roughly 8 billion injection […]
Lilly partners with four companies on insulin pen tech
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly’s latest insulin pen. The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will […]
Tandem Diabetes Care beats The Street in Q1, raises guidance
Tandem Diabetes Care (NSDQ:TNDM) narrowed its losses year-over-year in Q1, with results beating the consensus forecast on Wall Street. The San Diego-based company yesterday evening posted losses of –$5 million, or –8¢ per share, on sales of $141 million for the three months ended March 31, 2021, reducing losses by nearly two-thirds on sales growth […]
Kala Pharmaceuticals rises before hours on mixed bag Q1
Kala Pharmaceuticals (NSDQ:KALA) announced shares ticked up before hours today on first-quarter results that were mixed compared to the consensus forecast. The Watertown, Mass.-based company posted losses of -$30.4 million, or -49¢ per share, on sales of $3.2 million for the three months ended March 31, 2021, for a -38.5% bottom-line slide despite revenues that more […]